Cardiomyopathy

Clinical Trial Finder

Many patients with cardiomyopathy are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Prediction of Sudden Cardiac Death in Dilated Cardiomyopathy

Conditions:   Cardiomyopathy, Dilated;   Sudden Cardiac Death
Intervention:   Diagnostic Test: Cardiac Magnetic Resonance Imaging
Sponsor:   University Hospital Heidelberg
Recruiting - verified July 2017

The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - PARTNER II - Nested Registry 3/Valve-in-Valve

Conditions:   Aortic Stenosis;   Cardiomyopathy, Hypertrophic
Intervention:   Device: Edwards SAPIEN XT transcatheter valve, Model 9300TFX
Sponsor:   Edwards Lifesciences
Active, not recruiting - verified July 2017

A Study of Anemia in Children With Dilated Cardiomyopathy

Condition:   Pediatric Dilated Cardiomyopathy
Intervention:  
Sponsor:   Assiut University
Not yet recruiting - verified July 2017

Natural History in Fabry Patients With IVS4+919G>A Mutation

Condition:   Fabry Disease, Cardiac Variant
Intervention:   Behavioral: Family pedigree and data collection
Sponsors:   Taipei Veterans General Hospital, Taiwan;   Sanofi
Not yet recruiting - verified July 2017

Contrast ICE for Myocardial Scar in VT Ablations

Conditions:   Ventricular Tachycardia;   Ischemic Cardiomyopathy
Intervention:   Drug: Perflutren Lipid Microsphere Intravenous Suspension [DEFINITY]
Sponsors:   Weill Medical College of Cornell University;   Biosense Webster, Inc.
Active, not recruiting - verified July 2017

Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency

Condition:   Iron-deficiency
Interventions:   Drug: Ferric Carboxymaltose;   Drug: Placebo
Sponsor:   New York University School of Medicine
Not yet recruiting - verified July 2017

Gene Transfer Clinical Study in Crigler-Najjar Syndrome

Condition:   Crigler-Najjar Syndrome
Intervention:   Genetic: AT342
Sponsor:   Audentes Therapeutics
Not yet recruiting - verified July 2017

Risk Factors for Predictors of In-hospital Death in Acute Fulminant Myocarditis

Conditions:   Viral Myocarditis;   Cardio-Renal Syndrome;   Risk Factor, Cardiovascular
Intervention:   Other: prognosis
Sponsor:   The First Affiliated Hospital of Soochow University
Completed - verified July 2017

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction

Condition:   Heart Failure
Interventions:   Drug: Neladenoson bialanate (BAY1067197);   Drug: Neladenoson bialanate (BAY1067197);   Drug: Neladenoson bialanate (BAY1067197);   Drug: Neladenoson bialanate (BAY1067197);   Drug: Neladenoson bialanate (BAY1067197);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified July 2017

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

Condition:   Heart Failure With Preserved Ejection Fraction
Interventions:   Drug: sacubitril/valsartan;   Drug: Enalapril;   Drug: Valsartan;   Drug: Placebo to match sacubitril/valsartan;   Drug: Placebo to match enalapril;   Drug: Placebo to match valsartan
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting - verified July 2017

In and ex Vivo Mitochondrial Function of the Heart

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Cardiomyopathies
Interventions:   Diagnostic Test: 31P-MRS scan and cardiac MRI scan;   Diagnostic Test: Atrial biopsy for high-resolution respirometry;   Diagnostic Test: Blood analysis;   Diagnostic Test: Body composition;   Diagnostic Test: Indirect Calorimetry
Sponsors:   Maastricht University Medical Center;   Diabetes Fonds
Enrolling by invitation - verified July 2017

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

Condition:   Heart Failure
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2017

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

Condition:   Heart Failure
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2017

Empagliflozin Impact on Hemodynamics in Patients With Diabetes and Heart Failure

Condition:   Heart Failure
Interventions:   Drug: Empagliflozin 10Mg Tab;   Drug: Placebo Oral Tablet
Sponsor:   Saint Luke's Health System
Recruiting - verified July 2017

Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction

Condition:   Heart Failure
Interventions:   Drug: Omecamtiv Mecarbil;   Drug: Placebo
Sponsors:   Amgen;   Cytokinetics;   Servier
Recruiting - verified July 2017

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Condition:   Transthyretin (TTR) Amyloid Cardiomyopathy
Intervention:   Drug: Tafamidis meglumine
Sponsor:   Pfizer
Recruiting - verified July 2017

Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure

Condition:   Hypertrophic Cardiomyopathy
Interventions:   Drug: Perhexiline;   Drug: Placebo
Sponsor:   Heart Metabolics Limited
Withdrawn - verified July 2017

CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)

Condition:   Chagas Disease
Interventions:   Drug: Nifurtimox;   Drug: Benznidazole;   Drug: Placebo
Sponsors:   Universidad Autónoma de Bucaramanga;   Fundación Cardioinfantil Instituto de Cardiología;   Instituto Nacional de Salud (Colombia);   Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben
Recruiting - verified July 2017

Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease

Condition:   BRAF V600E Mutation
Interventions:   Drug: Dabrafenib Mesylate;   Drug: Trametinib Dimethyl Sulfoxide
Sponsor:   National Human Genome Research Institute (NHGRI)
Suspended - verified July 11, 2017

Effect of RIC on Clinical Outcomes in STEMI Patients Undergoing pPCI

Condition:   Myocardial Reperfusion Injury
Intervention:   Procedure: Remote Ischaemic Conditioning
Sponsors:   Aarhus University Hospital;   Rigshospitalet, Denmark;   Aalborg Universitetshospital;   Odense University Hospital;   Hospital Universitario Central de Asturias;   Clinical Centre of Serbia;   Military Medical Academy, Belgrade, Serbia;   The Hatter Cardiovascular Institute, London W, United Kingdom;   Central Denmark Region;   Region of Southern Denmark;   Prehospital Emergency Medical Service, The North Denmark Region;   Region Zealand;   The Danish Medical Research Council
Recruiting - verified October 2016

Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial)

Conditions:   Mitral Regurgitation;   Mitral Valve Regurgitation;   Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure Subjects;   Heart Failure
Intervention:   Device: MitraClip System
Sponsors:   Evalve;   Abbott Vascular
Recruiting - verified July 2017